Fig. 1From: Salvage pembrolizumab added to kinase inhibitor therapy for the treatment of anaplastic thyroid carcinomaWaterfall plot demonstrating response to combination of kinase inhibitor therapy and pembrolizumab: A partial response was observed in 5/12 (42%), stable disease in 4/12 (33%) and progressive disease in 3/12 (25%). The box below the patient number describes the PD-L1 status on the tumor tissueBack to article page